38 results about "Kidney dysfunction" patented technology

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention relates to the field of medical treatment, in particular to application, a model and a method of a protein fragment of urine regulatory protein in preparation of a kidney disease early detection product, and the amino acid sequence of the protein fragment of the urine regulatory protein is any shown in SEQ ID NO.1-8. The model constructed according to the protein fragment of the urine regulatory protein can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and by analyzing the unique mode of the protein fragment existing in a urine sample, the model which indicates renal insufficiency, renal function and renal function can be identified before the traditional clinical biomarker is abnormal. Therefore, intervention can be carried out earlier.

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

The present disclosure provides methods of treating multiple sclerosis associated spasticity or neurological pain in a patient with renal impairment by administering cannabinoids oromucosal spray.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

The invention provides a risk prediction model processing method and device for a patient with coronary heart disease complicated with renal insufficiency, and introduces a machine learning technology to configure a risk prediction model for the patient with coronary heart disease complicated with renal insufficiency under the condition of paying attention to the neglected relationship between coronary heart disease complicated with renal insufficiency and hospitalization death in the prior art. Further specific optimization is continuously carried out on characteristic variable indexes related to risk prediction logic of the patient with coronary heart disease and renal insufficiency layer by layer in a deep aspect, so that the incidence relation between the patient with coronary heart disease and renal insufficiency and hospitalization death can be deeply captured; the hospitalization death risk prediction work of the patient with coronary heart disease and renal insufficiency is completed with high precision, accurate data support is provided for hospitalization risk assessment and hospitalization management work of the patient with coronary heart disease and renal insufficiency, and then better medical service quality and safety guarantee are provided.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition, a method for reducing the serum uric acid level of a gout patient and application of topiromilast to preparation of a medicine for treating hyperuricemia / gout with hyperuricemia. The medicine is continuously administered according to the following dosage scheme: the initial dosage is 40-80mg / day, and the duration period is 2-4 weeks; the first adjusting dosage is 120-160mg / day, and the duration period is 2-4 weeks; the maximum dose is 160-320 mg / day, and the dose lasts for at least 8 weeks. According to the pharmaceutical composition, high-efficiency treatment of Chinese patients with hyperuricemia / gout is realized through a staged dosage increasing scheme, and renal function impairment is improved. The invention further provides a method for reducing the serum uric acid level of gout patients, continuous administration is carried out according to the dosage scheme, and the topiromilast is applied to preparation of the medicine for treating hyperuricemia / gout with hyperuricemia and is suitable for people with renal insufficiency.

The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

The present invention relates to a method for measuring post-translational modification of proteins in a subject. The method comprises recording infrared radiation in a predetermined wave number range attenuated by an integument of the subject, wherein the integument is still attached to the subject; and comparing the attenuation of the infrared radiation to a predetermined value in order to obtain information about post-translational modification of proteins in the integument. The present invention also relates to a corresponding system and post-translationally modified integument proteins as markers for in vivo diagnosis of diseases, such as diabetes or renal insufficiency.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The invention relates to a traditional Chinese medicine composition for treating acute kidney injury and a preparation method, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-30 parts of raw radix astragali; 10-15 parts of codonopsis pilosula; 10 parts of rhizoma pinellinae praeparata; 10 parts of pericarpium citri reticulatae; 15 to 30 parts of loofah sponge; 15 to 30 parts of serissa japonica; and 15-30 parts of rhizoma smilacis glabrae. The traditional Chinese medicine composition disclosed by the invention has two treatment methods of tonifying qi and relieving turbidity, realizes multiple ways, treats both symptoms and root causes, is promoted to be new, has the functions of tonifying qi and relieving turbidity, has a remarkable clinical effect on treating acute renal insufficiency, and has a very good effect in the aspects of improving renal functions and protecting kidneys.

The present invention relates to the use of ADAMTS12 protein, a disintegrin and metalloproteinase 12 protein having a platelet-reactive protein motif, in the development of chronic kidney diseases, in particular progressive chronic kidney diseases and renal fibrosis. In particular, the present invention relates to a method for identifying compounds that bind to ADAMTS12 protein and the use of ADAMTS12 protein for screening and identifying ADAMTS12 interacting compounds and ADAMTS12 inhibiting compounds. The present invention also relates to pharmaceutical compositions for the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit ADAMTS12 protein (Fig. 5).

The present disclosure provides a palatable composition in a solid gel form for a companion animal, said palatable composition comprising at least from about 90wt% to about 99wt% of broth, said broth comprising at least about 90wt% of water compared to the total weight of the broth, from about 0.1 wt% to about 2wt% of at least one texturing agent, and from about 0.1 wt% to about 4wt% of at least one mineral salt. It further provides a package comprising from about 20ml to about 200ml of said palatable composition, a method for manufacturing said palatable composition, as well as its use for improving the hydration of a companion animal, for providing fast rehydration to a companion animal during effort and in preventing and / or treating a kidney dysfunction.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (A disintegrin and metalloproteinase with thrombospondin motifs 12-protein) in the pathogenesis of chronic kidney and heart diseases and in particular chronic renal insufficiency and renal fibrosis or cardiac insufficiency and cardiac fibrosis. The present invention relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, and to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active ingredients that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and / or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.

The present disclosure relates to an animal food composition including from about 0.3 g / Mcal to about 0.8 g / Mcal of magnesium or a salt thereof, for use in a method for treating and / or preventing a mineral bone disorder, especially mineral bone disorder associated with hypercalcemia, in a companion animal that is affected by, or at risk to be affected by, a kidney dysfunction.

The invention relates to the field of medical treatment, in particular to application, a model and a method of urine polypeptide in preparation of a product for early detection of renal function progression, and the mass-to-charge ratio of the urine polypeptide is any one or more of m / z 1378.8, m / z 1725.95, m / z 1902.7, m / z 1933.8, m / z 2234.26, m / z 2752.42, m / z 1013.59, m / z 1235.53, m / z 1911.76, m / z 2039.86, m / z 1949.9, m / z 1869.59, m / z 2086.71, m / z 1641.2 and m / z 3321.3. A model constructed according to the urine polypeptide can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and renal insufficiency can be identified and indicated before a traditional clinical biomarker is abnormal by analyzing a unique mode of the polypeptide existing in a urine sample, so that intervention can be performed earlier.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a multi-component traditional Chinese medicine external lotion for improving the itching symptom of a chronic kidney disease patient, which is technically characterized in that the lotion is prepared by extracting, concentrating and preparing raw rehmannia root, moutan bark, fructus kochiae, cortex dictamni, salvia miltiorrhiza, radix angelicae sinensis, radix polygoni multiflori preparata, radix sophorae flavescentis and borneol according to a specific weight part ratio. The scheme of the invention integrates treatment methods of nourishing kidney and yin, promoting blood circulation to remove blood stasis, clearing heat and expelling dampness, and cooling blood and dispelling wind aiming at the core pathogenesis of CKD itching of liver and kidney yin deficiency, damp turbidity and blood stasis and skin dystrophy, and is assisted with borneol to promote penetration. Compared with the prior art, the traditional Chinese medicine composition is scientific in formula compatibility, treats both symptoms and root causes and has synergistic interaction; moreover, the scheme of the invention directly acts on the pruritus skin in the form of external lotion, has the advantages of quick response, convenience in use and high safety, is particularly suitable for CKD patients with renal insufficiency, and can obviously relieve pruritus and improve life quality and sleep.

The application belongs to the technical field of functional microorganisms, and discloses application of Pediococcus pentosaceus A21243 in lowering blood uric acid and improving kidney function, and provides application of the Pediococcus pentosaceus A21243 in preparing products for preventing or treating nephropathy and hyperuricemia, wherein the Pediococcus pentosaceus is Pediococcus pentosaceus A21243, and the preservation number is GDMCC NO:63749. The Pediococcus pentosaceus A21243 has the effects of improving and delaying kidney dysfunction caused by hyperuricemia, hyperglycemia and cisplatin, meanwhile, the strain can inhibit the activity of purine metabolism related enzymes in the uric acid generation pathway, such as inhibiting the activity of xanthine oxidase (XOD), purine nucleoside phosphorylase (PNP) and adenosine deaminase (ADA), promote the excretion of uric acid through the intestinal feces, regulate the oxidative stress disorder caused by hyperuricemia, and achieve the beneficial effect of lowering blood uric acid.

The present disclosure relates to an animal food composition including from about 0.3 g / Mcal to about 0.8 g / Mcal of magnesium or a salt thereof, for use in a method for treating and / or preventing a mineral bone disorder, especially mineral bone disorder associated with hypercalcemia, in a companion animal that is affected by, or at risk to be affected by, a kidney dysfunction.

Provided are a computer program, an information processing device, and an information processing method. 　The computer program makes a computer execute a processing that includes: evaluating the body water storage state in a patient having heart failure or renal dysfunction; determining whether or not the taking of a diuretic drug should be recommended on the basis of a result of the evaluation; and notifying a terminal device for the patient about a proposal relating to the taking of the diuretic drug on the basis of a result of the determination.

The invention relates to the technical field of biology and information, and discloses an anti-infection clinical decision support system, which comprises the following modules: a various antibacterial drug characteristic module (1); an antibacterial drug pharmacokinetic module (2); a renal insufficiency dose adjustment module (3), wherein the renal insufficiency dose adjustment module (3) comprises a renal insufficiency dose adjustment-free drug module (31) and a creatinine clearance rate calculation module (32); a liver insufficiency dose adjustment module (4), wherein the liver insufficiency dose adjustment module (4) comprises a liver function impairment Child-Pugh grading module (41) and a liver insufficiency dose adjustment-free drug module (42); a national bacterial drug resistance statistics module (5); and a drug antibacterial spectrum query module (6). According to the anti-infection clinical decision support system, through cooperative operation of the six modules, all-around support is provided for clinical anti-infection diagnosis and treatment.

The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.

The present invention relates to the role of ADAMTS12 protein (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 12 protein) in the development of chronic kidney disease, in particular progressive chronic kidney disease and renal fibrosis. In particular, the present invention relates to methods for identifying compounds that bind to the ADAMTS12 protein and to the use of ADAMTS12 protein for screening and identifying ADAMTS12-interacting and ADAMTS12-inhibiting compounds. The present invention further relates to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit the ADAMTS12 protein.

This invention discloses a copper dicyclopentyl dithiocarbamate compound and its applications, relating to the field of pharmaceutical chemistry, with the molecular formula C0. 22 H 36 CuN2S4, with a central copper ion and two dicyclopentyl dithiocarbamate ligands coordinated via sulfur atoms to form a four-coordinate planar square structure, or its pharmaceutically acceptable salts, solvates, crystal forms, or hydrates. This invention utilizes a novel chemical entity of dicyclopentyl-substituted copper dithiocarbamate, leveraging the greater steric hindrance and lipophilicity advantages of its cyclopentyl structure, as well as its selective response to the high-copper microenvironment of cholangiocarcinoma. Furthermore, it exhibits strong targeting, achieving high enrichment in liver and cholangiocarcinoma tissues, broadening the therapeutic index. Simultaneously, by avoiding the inhibition of systemic ALDH2 activity, it eliminates the alcohol-like toxicity caused by acetaldehyde accumulation. Moreover, it does not cross the blood-brain barrier, exhibits no significant neurotoxicity or cardiotoxicity, is patient-friendly for those with renal insufficiency, and demonstrates high safety.

Provided herein are methods of administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-phenylbutyric acid (4-PBA) or a pharmaceutically acceptable salt thereof to a subject with renal impairment. Also provided are methods of treating a neurodegenerative disease in a subject with renal impairment, comprising administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-PBA or a pharmaceutically acceptable salt thereof to the subject.

The invention discloses a method, a system and a product for predicting unilateral renal function grading based on CT subtraction imaging, and the method comprises the steps: firstly, extracting a cortical medullary enhancement period CTU image of a patient, and obtaining a plain-scan CTU image and an enhanced CTU image; then aligning the plain-scan CTU image and the enhanced CTU image; automatically segmenting the bilateral renal cortex by using a neural network model, and further reasoning to obtain a renal cortex mask; constructing a subtraction imaging mode by pixel-by-pixel subtraction based on the registered enhanced image and the plain-scanned image; then extracting subtraction imaging modal radiation group features to obtain unilateral kidney radiomics features; and finally, predicting the kidney function based on the kidney function prediction model. According to the method, the recognition precision of the kidney cortex area is improved, interference features are eliminated, the signal-to-noise ratio is improved, and the kidney function of the patient with total renal insufficiency is accurately and noninvasively predicted. Valuable guidance can be provided for clinical decision making, and clinicians can be helped to better evaluate patients suffering from total renal insufficiency.

The invention belongs to the technical field of biology, and particularly relates to application of lupeol to preparation of a medicine for preventing or treating renal injury caused by cis-platinum. The invention discovers that the natural compound lupeol has a potential protection effect on the renal injury caused by the cis-platinum for the first time, and in-vivo and in-vitro models prove that the lupeol remarkably relieves renal dysfunction, tissue pathological injury and rising of renal injury markers caused by the cis-platinum, inhibits cell apoptosis and promotes proliferation of renal tubular cells. A transcriptome sequencing result shows that lupeol enhances cell survival and proliferation by activating a PI3K / Akt signal channel, regulates an Nrf2 channel to resist oxidative stress, inhibits nuclear translocation of NF [kappa] B, reduces pro-inflammatory cytokines and inhibits inflammatory response. Results show that lupeol may become a choice for relieving renal toxicity of cis-platinum.

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.